Evolent Health Reports Q3 2026 Revenue Growth and Raises Full-Year Adjusted EBITDA Guidance
Evolent Health (EVH) reported strong third-quarter results for 2026, with revenue reaching $725.4 million, an 11% increase from the previous quarter. This growth was primarily driven by the expansion of its Performance Suite and favorable contractual adjustments. The company also saw a significant improvement in its medical expense ratio, which dropped to 93%, reflecting better management of claims development. Driven by these results, Evolent Health raised its full-year adjusted EBITDA guidance to a range of $130 million to $135 million. Looking ahead, the company is targeting an adjusted EBITDA of at least $150 million for 2027, supported by upcoming oncology service expansions and cost reduction initiatives. While membership attrition in Medicaid remains a headwind, management's focus on AI-driven auto-authorization and debt reduction aims to enhance long-term financial flexibility.
Topics: EBITDA guidance medical expense ratio performance suite expansion revenue growth